---
title: "Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 | LUCD Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284773275.md"
description: "Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call and webcast on May 14, 2026, at 8:30 AM ET. CEO Lishan Aklog will discuss the company's operations and growth strategy, while CFO Dennis McGrath will present the first quarter 2026 financial results. The event can be accessed via the company's website or by telephone. A replay will be available for 30 days post-call. Lucid focuses on cancer prevention through its EsoGuard® Esophageal DNA Test for patients at risk of esophageal cancer."
datetime: "2026-04-30T04:31:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284773275.md)
  - [en](https://longbridge.com/en/news/284773275.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284773275.md)
---

# Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026 | LUCD Stock News

_Conference Call and Webcast at 8:30 AM ET_

, /PRNewswire/ -- **Lucid Diagnostics Inc.** **(Nasdaq: LUCD)** ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, May 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2026 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

**About Lucid Diagnostics  
**Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics

### Related Stocks

- [LUCD.US](https://longbridge.com/en/quote/LUCD.US.md)
- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)
- [PAVMZ.US](https://longbridge.com/en/quote/PAVMZ.US.md)

## Related News & Research

- [Lucid Diagnostics Reports Q1 2026 Results and Outlook](https://longbridge.com/en/news/286419963.md)
- [Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock | LUCD Stock News](https://longbridge.com/en/news/284020712.md)
- [Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | POCI Stock News](https://longbridge.com/en/news/286816732.md)
- [Northern Trust Leaders to Participate in Morgan Stanley 2026 US Financials Conference on June 9 | NTRS Stock News](https://longbridge.com/en/news/286824408.md)
- [Jaguar Health publishes financial calendar update](https://longbridge.com/en/news/287070752.md)